Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | KLK7 | P49862 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSH | P09668 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698470 | 0.77 | EPHX1 (0.46) | EPHX1SMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL4480834 | 0.77 | EPHX1 (0.41) | CTSKLMNAEPHX1SMN1; SMN2 | |
| SCHEMBL4480821 | 0.77 | EPHX1 (0.38) | CTSKKLK7METAP2EPHX1SMN1; SMN2 | |
| SCHEMBL6894933 | 0.77 | EPHX1 (0.38) | CTSKKLK7METAP2EPHX1SMN1; SMN2 | |
| SCHEMBL696982 | 0.76 | EPHX1 (0.44) | KLK7EPHX1SMN1; SMN2MEN1MAPT | |
| SCHEMBL13692816 | 0.75 | EPHX1 (0.34) | CTSKKLK7METAP2EPHX1SMN1; SMN2 | |
| SCHEMBL4481790 | 0.73 | ALDH1A1 (0.43) | LMNASMN1; SMN2MAPT | |
| SCHEMBL698517 | 0.72 | EPHX1 (0.40) | EPHX1SMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL4487087 | 0.72 | — | — | |
| SCHEMBL4484124 | 0.71 | TSHR (0.36) | LMNASMN1; SMN2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553989-B2 | Malonic acid monoesters and process for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-30 | — | — | US | claimed |
| US-20050272950-A1 | Malonic acid monoesters and process for producing the same | MEIJI SEIKA KAISHA LTD. (JP) | 2005-12-08 | — | — | US | claimed |
| EP-1561748-A1 | MALONIC ACID MONOESTERS AND PROCESS FOR PRODUCING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2005-08-10 | — | — | EP | claimed |
| US-7553989-B2 | Malonic acid monoesters and process for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20050272950-A1 | Malonic acid monoesters and process for producing the same | MEIJI SEIKA KAISHA LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1561748-A1 | MALONIC ACID MONOESTERS AND PROCESS FOR PRODUCING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2005-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272950-A1 | Malonic acid monoesters and process for producing the same | ME1, SI, ME3 | CTSK 2232/4885KLK7 2462/4885LMNA 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.